Evelyne Delfourne
Paul Sabatier University
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Evelyne Delfourne.
Marine Drugs | 2009
Sébastien Deslandes; Stefan Chassaing; Evelyne Delfourne
Granulatimide and isogranulatimide are alkaloids obtained from marine sources which have been shown to inhibit cell-cycle G2-checkpoint, targeting more particularly checkpoint 1 kinase (Chk1). At a structural level, they possess a characteristic pyrrolocarbazole framework also shared by the well-known rebeccamycin and staurosporine microbial metabolites which have been described to inhibit topoisomerase I and diverse kinases, respectively. This review reports precisely on the synthesis and kinase inhibitory activities of pyrrolocarbazole-based analogues of granulatimide.
Bioorganic & Medicinal Chemistry Letters | 2013
Eduard Dolusic; Pierre Larrieu; Céline Meinguet; Delphine Colette; Arnaud Rives; Sébastien Blanc; Thierry Ferain; Luc Pilotte; Vincent Stroobant; Johan Wouters; Benoît Van den Eynde; Bernard Masereel; Evelyne Delfourne; Raphaël Frédérick
Tsitsikammamines are marine alkaloids whose structure is based on the pyrroloiminoquinone scaffold. These and related compounds have attracted attention due to various interesting biological properties, including cytotoxicity, topoisomerase inhibition, antimicrobial, antifungal and antimalarial activity. Indoleamine 2,3-dioxygenase (IDO1) is a well-established therapeutic target as an important factor in the tumor immune evasion mechanism. In this preliminary communication, we report the inhibitory activity of tsitsikammamine derivatives against IDO1. Tsitsikammamine A analogue 11b displays submicromolar potency in an enzymatic assay. A number of derivatives are also active in a cellular assay while showing little or no activity towards tryptophan 2,3-dioxygenase (TDO), a functionally related enzyme. This IDO1 inhibitory activity is rationalized by molecular modeling studies. An interest is thus established in this class of compounds as a potential source of lead compounds for the development of new pharmaceutically useful IDO1 inhibitors.
European Journal of Medicinal Chemistry | 2012
Sébastien Deslandes; Delphine Lamoral-Theys; Céline Frongia; Stefan Chassaing; Céline Bruyère; Olivier Lozach; Laurent Meijer; Bernard Ducommun; Robert Kiss; Evelyne Delfourne
A series of pyrrolic analogs and two series of regioisomeric pyrazolic analogs of the marine alkaloids granulatimide and isogranulatimide were prepared. The synthesis of the two first ones was based on the condensation reaction of diversely 5-substituted 3-bromoindoles with pyrrole or pyrazole followed by addition of the intermediates on maleimide or dibromomaleimide, respectively, the so-obtained acyclic adducts being finally photocyclized to the desired analogs. Compounds of the last series were obtained by reacting different 5-substituted-indole-3-glyoxylates with N-Boc-pyrazole-3-acetamide and subsequent photochemical cyclization of the adducts. All the compounds were evaluated for their in vitro growth inhibitory properties toward eight cancer cell lines. Several compounds were also assayed for their ability to abrogate the G2-cell cycle checkpoint or to inhibit a panel of Ser/Thr kinases. Lastly, computer-assisted phase-contrast microscopy (quantitative videomicroscopy) revealed that the three most potent compounds (4a, 9a, 9e), with IC(50) growth inhibitory concentrations ranging between 10 and 20 μM, displayed cytostatic, not cytotoxic, anticancer effects.
Bioorganic & Medicinal Chemistry | 2014
Hubert Lavrard; Frédéric Rodriguez; Evelyne Delfourne
The two marine alkaloids granulatimide and isogranulatimide have been shown to inhibit the checkpoint kinase 1 (Chk1), a promising target for cancer treatment. A molecular docking study allowing the design of new potential Chk1 inhibitors based on the natural products skeleton and the synthetic work to an amino-target platform to prepare them are described.
ChemMedChem | 2015
Hubert Lavrard; Béatrice Salvetti; Véronique Mathieu; Frédéric Rodriguez; Robert Kiss; Evelyne Delfourne
Marine organisms have proven to be a promising source of new compounds with activity against tumor cell lines. Granulatimide and isogranulatimide are marine alkaloids that have been shown to inhibit checkpoint kinase 1 (Chk1), a key protein in the DNA damage response and an emerging target for anticancer therapeutics. Here, we describe the synthesis and preliminary evaluation of amido and amino analogues of isogranulatimide. The new derivatives were prepared in three steps from 2‐imidazol‐1‐yl‐1H‐indol‐5‐ylamine. Two of the compounds synthesized exhibited more potent in vitro antiproliferative activity (single‐digit micromolar concentration range), by at least one log of magnitude, than the natural product isogranulatimide when evaluated in six human tumor cell lines: non‐small‐cell lung cancer (A549), colon cancer (LoVo), breast cancer (MCF7), oligodendroglioma (Hs683), glioblastoma (U373), and melanoma (SKMEL28). The mechanism of action of these derivatives remains to be elucidated, given that they did not significantly inhibit Chk1, however these compounds are easily synthesized and exhibit potent anticancer activity and are thus worthy of further study.
Chemical Biology & Drug Design | 2016
Rémi Safi; Frédéric Rodriguez; Georges Hilal; Mona Diab-Assaf; Youssef Diab; Marwan El-Sabban; Fadia Najjar; Evelyne Delfourne
The natural product ferutinin was shown to act as an agonist to estrogen receptor ERα and agonist/antagonist to ERβ featuring a weak antiproliferative activity toward breast cancer cells. To enhance this activity, ferutinin analogues were synthesized by esterification of jaeschkenadiol with different acids. These compounds were assayed for their in vitro antiproliferative activity against estrogen‐dependent (MCF‐7) and estrogen‐independent (MDA‐MB‐231) breast cancer cell lines. Among the compounds, 3c’ exhibited a potent inhibitory selective activity against MCF‐7 with IC50 value of 1 μm. Docking simulation of 3c’ in the ligand binding domain of the ERs indicated a potential antagonism interaction with both ER subtypes. Functional assay showed that 3c’ binds as an antagonist to ERα protein while ferutinin acts as an agonist.
Tetrahedron Letters | 1988
Evelyne Delfourne; Liliane Gorrichon; Chantal Zedde
Abstract Chiral dioxolans have been synthesized from (-)methyl shikimate and β-ketoesters in order to mimic the enolization process postulated in the enzyme dehydroquinate hydrolyase mechanism. We expect the (R) isomers to be better recognized by the enzyme. The configuration of the newly created asymmetric center in the dioxolan has been determined by 2D 1 H and 13 C NMR.
Magnetic Resonance in Chemistry | 2009
Stefan Chassaing; Evelyne Delfourne
The structural assignment of bispyrroloquinone and bispyrroloiminoquinone regioisomers was achieved using 13C NMR spectral data. In the case of bispyrroloiminoquinones, the carbonyl group in the regioisomer possessing a nitrogen atom in both α‐positions was systematically less deshielded than the carbonyl group in the other regioisomer. In the case of bispyrroloquinones, the most deshielded carbonyl group in the regioisomer with a nitrogen atom in both α‐positions was more deshielded than the same carbonyl group in the other regioisomer. Copyright
Biochimica et Biophysica Acta | 2005
Lionel Guittat; Anne De Cian; Frédéric Rosu; Valérie Gabelica; Edwin De Pauw; Evelyne Delfourne; Jean-Louis Mergny
Bioorganic & Medicinal Chemistry Letters | 2006
Laurent Legentil; Brigitte Lesur; Evelyne Delfourne